- Title
- PR029/#943 A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301
- Creators
- Rachel Grisham - Memorial Sloan Kettering Cancer CenterBradley Monk - Florida Cancer Specialists, West Palm Beach, USAEls Van Nieuwenhuysen - University Hospitals Leuven, Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, BelgiumKathleen Moore - OU Health Stephenson Cancer CenterMichel Fabbro - Institut du Cancer de Montpellier (ICM) Val d’Aurelle Parc Euromedecine, Oncologie Médicale, GINECO, Montpellier, FranceDavid O’Malley - The Ohio State UniversityAna Oaknin - Hebron UniversityPremal Thaker - Washington University School of Medicine and Siteman Cancer Center in St. Louis, St. , Louis, USAAmit Oza - Princess Margaret Cancer CentreNicoletta Colombo - MylanStephanie Lustgarten - VerastemHagop Youssoufian - VerastemSusana Banerjee - Royal Marsden NHS Foundation Trust
- Publication Details
- International journal of gynecological cancer, Vol.34, pp.A53-A54
- Publisher
- Elsevier Inc
- Identifiers
- 991006133436702656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
PR029/#943 A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301
International journal of gynecological cancer, Vol.34, pp.A53-A54
10/2024
Metrics
1 Record Views